Apimostinel + Automated Neurocognitive Training for Depression - Trial NCT06400121
Access comprehensive clinical trial information for NCT06400121 through Pure Global AI's free database. This Phase 2 trial is sponsored by Rebecca Price and is currently Not yet recruiting. The study focuses on Depression. Target enrollment is 150 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Rebecca Price
University of Pittsburgh
Timeline & Enrollment
Phase 2
Jun 01, 2024
Dec 01, 2028
Primary Outcome
Montgomery-Asberg Depression Rating Scale (MADRS),Montgomery-Asberg Depression Rating Scale (MADRS)
Summary
Apimostinel shows initial promise as a novel rapid-acting antidepressant medication with
 minimal side effects or safety concerns. Cognitive Training (CT) is a digital intervention
 that has shown promise in extending the durability of another similar drug (ketamine). This
 randomized controlled trial will test the efficacy and safety of apimostinel (vs. saline) for
 the acute treatment of depression, and will test the potential of CT to enhance and/or extend
 the durability of apimostinel's antidepressant effect.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06400121
Non-Device Trial